Merck & Co., Inc. (MRK) Target Price Boosted to $84.00 at BMO Capital Markets

Merck & Co., Inc. (MRK) Target Price Boosted  to $84.00 at BMO Capital Markets

Merck & Co., Inc. (NYSE:MRK) had its price objective upped by BMO Capital Markets from $83.00 to $84.00 in a report released on Wednesday morning, AnalystRatings.com reports. BMO Capital Markets currently has a market perform rating on the stock.

A number of other analysts have also issued reports on the company. ValuEngine lowered Merck & Co., Inc. from a buy rating to a hold rating in a research note on Thursday, April 18th. Zacks Investment Research raised Merck & Co., Inc. from a hold rating to a buy rating and set a $93.00 price target on the stock in a research note on Monday, April 1st. Cantor Fitzgerald reissued a buy rating and issued a $95.00 price target on shares of Merck & Co., Inc. in a research note on Friday, March 29th. Finally, Argus raised their price target on Merck & Co., Inc. to $95.00 and gave the stock a buy rating in a research note on Wednesday, February 20th. Three investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. The stock presently has a consensus rating of Buy and a consensus price target of $82.92.

Shares of MRK traded up $0.48 during trading hours on Wednesday, reaching $80.00. 7,513,345 shares of the company traded hands, compared to its average volume of 12,762,064. The company has a quick ratio of 0.92, a current ratio of 1.17 and a debt-to-equity ratio of 0.74. The firm has a market cap of $215.70 billion, a P/E ratio of 17.74, a PEG ratio of 1.89 and a beta of 0.58. Merck & Co., Inc. has a fifty-two week low of $56.26 and a fifty-two week high of $83.85.

Merck & Co., Inc. (NYSE:MRK) last posted its quarterly earnings data on Tuesday, April 30th. The company reported $1.22 EPS for the quarter, beating analysts’ consensus estimates of $1.05 by $0.17. The business had revenue of $10.82 billion for the quarter, compared to analyst estimates of $10.45 billion. Merck & Co., Inc. had a return on equity of 38.85% and a net margin of 19.50%. The business’s revenue for the quarter was up 7.8% compared to the same quarter last year. During the same quarter last year, the company earned $1.05 earnings per share. As a group, equities analysts expect that Merck & Co., Inc. will post 4.72 EPS for the current fiscal year.

In other Merck & Co., Inc. news, major shareholder Merck & Co., Inc. purchased 4,121,683 shares of the firm’s stock in a transaction on Monday, April 8th. The shares were purchased at an average cost of $16.00 per share, with a total value of $65,946,928.00. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Chairman Kenneth C. Frazier sold 231,566 shares of Merck & Co., Inc. stock in a transaction dated Tuesday, February 5th. The shares were sold at an average price of $78.08, for a total value of $18,080,673.28. Following the completion of the transaction, the chairman now directly owns 923,516 shares in the company, valued at $72,108,129.28. The disclosure for this sale can be found here. Over the last three months, insiders sold 1,094,632 shares of company stock worth $87,840,652. 0.27% of the stock is owned by corporate insiders.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in MRK. Martingale Asset Management L P lifted its stake in shares of Merck & Co., Inc. by 0.7% in the 3rd quarter. Martingale Asset Management L P now owns 694,680 shares of the company’s stock valued at $49,281,000 after purchasing an additional 5,121 shares in the last quarter. Trexquant Investment LP raised its holdings in shares of Merck & Co., Inc. by 77.9% during the 3rd quarter. Trexquant Investment LP now owns 73,063 shares of the company’s stock valued at $5,183,000 after buying an additional 31,998 shares during the period. Cobblestone Capital Advisors LLC NY raised its holdings in shares of Merck & Co., Inc. by 0.6% during the 3rd quarter. Cobblestone Capital Advisors LLC NY now owns 188,268 shares of the company’s stock valued at $13,356,000 after buying an additional 1,188 shares during the period. Schroder Investment Management Group raised its holdings in shares of Merck & Co., Inc. by 1.1% during the 3rd quarter. Schroder Investment Management Group now owns 5,161,859 shares of the company’s stock valued at $366,182,000 after buying an additional 54,841 shares during the period. Finally, Trust Co. of Virginia VA raised its holdings in shares of Merck & Co., Inc. by 3.3% during the 3rd quarter. Trust Co. of Virginia VA now owns 54,252 shares of the company’s stock valued at $3,849,000 after buying an additional 1,716 shares during the period. 73.51% of the stock is currently owned by institutional investors and hedge funds.

Merck & Co., Inc. Company Profile

Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.

Featured Article: What is a Tariff?

Related posts

Leave a Comment